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Different Modes of IL-10 and TGF- to Inhibit
Cytokine-Dependent IFN- Production: Consequences for
Reversal of Lipopolysaccharide Desensitization1
Martina Schröder, Christian Meisel, Katharina Buhl, Nina Profanter, Nadine Sievert,
Hans-Dieter Volk, and Gerald Grütz2
LPS hyporesponsiveness is characterized by a diminished production of proinflammatory cytokines which can be caused by
pretreatment with either LPS (LPS desensitization) or the combination of the anti-inflammatory cytokines IL-10 and TGF-.
However, the resulting hyporesponsive states differ regarding their reversibility by the IFN--inducing cytokine IL-12. Therefore,
we aimed at studying the reasons for this differential IL-12 responsiveness of IFN- producing cells and its consequences for LPS
hyporesponsiveness in more detail. In an in vitro IL-12/IL-18 responsiveness model, we demonstrated that IL-10, if permanently
present, does not directly inhibit IL-12/IL-18 responsiveness in T/NK cells but indirectly interferes with IFN- production in the
presence of monocytes. In contrast, TGF- acted directly on IFN--producing cells by interfering with IL-12/IL-18 responsiveness.
After removal of IL-10 but not of TGF- , LPS hyporesponsiveness can be reverted by IL-12/IL-18. Consequently, the addition of
recombinant TGF- during LPS desensitization rendered PBMCs hyporesponsive to a reversal by IL-12/IL-18. Our data suggest
that the persistence of IL-10 and the presence of TGF- determine the level of IFN- inhibition and may result in different
functional phenotypes of LPS desensitization and LPS hyporesponsiveness in vitro and in vivo.The Journal of Immunology, 2003,
170: 5260–5267.
A n excessive proinflammatory reaction as observed insepsis and after major surgery is often followed by adominant compensatory anti-inflammatory response
syndrome. Moreover, stress reactions triggered by head trauma can
directly lead to an anti-inflammatory response. All types can result
in an immunoparalytic state (“immunoparalysis”), if the anti-
inflammatory response is strong and long-lasting (1, 2). Monocytes
from immunoparalytic patients show an impaired production of
proinflammatory cytokines when stimulated with the bacterial cell
wall component endotoxin (LPS) ex vivo (3). Long-lasting immu-
noparalysis may therefore lead to a fatal outcome in critically ill
patients due to opportunistic infections (4, 5).
LPS desensitization is considered to be an experimental model
for immunoparalysis (6, 7). It describes the fact that monocytes
incubated with a low dose of LPS have a diminished capacity to
produce TNF- upon restimulation with a second higher dose of
LPS (8, 9). In addition, the production of IFN- by T/NK cells is
also reduced (10–12). We and others have previously shown that
the anti-inflammatory cytokines IL-10 and TGF- are involved in
mediating the process of LPS desensitization. Furthermore, IL-10
and TGF- can even directly induce a state of LPS hyporespon-
siveness (6, 13). Thus, low-dose LPS pretreatment and IL-10/
TGF- pretreatment both induce a similar phenotype of LPS
hyporesponsiveness.
Since IFN- has activating effects on monocytes, its decreased
expression in LPS hyporesponsiveness was likely to contribute to
impaired monocyte function. Indeed, monocyte dysfunction in-
duced by either LPS or IL-10/TGF- pretreatment was reversible
by exogenous IFN- (7). In addition, IFN- was able to revert LPS
tolerance in mice (14), to restore the diminished ex vivo TNF-
production of immunoparalytic patients, and to improve their clin-
ical outcome (4). These results clearly suggest IFN- as a key
regulator in this system. After LPS treatment, several IFN--in-
ducing stimuli are produced by monocytes. One of these factors is
IL-12, which is strongly diminished during LPS desensitization
and has been demonstrated to be the main IFN--inducing factor in
this system (11). It was therefore surprising that IL-12 was able to
restore LPS responsiveness only in LPS-desensitized PBMCs but
not in IL-10/TGF--pretreated PBMCs nor in cells from septic
patients (7, 15). This observation suggested differences in IL-12
responsiveness of IFN--producing cells and raised the question
which of the in vitro LPS hyporesponsiveness models reflects the
situation in immunoparalytic patients best.
IL-10 is known to modulate T cell responses mainly via its
suppressive effects on APCs, e.g., by down-regulation of HLA-DR
expression (16–18) and by the inhibition of proinflammatory cy-
tokines including IL-12 (19, 20). However, direct inhibitory effects
of IL-10 on T cell function and differentiation have also been de-
scribed (21), including inhibition of IL-2 production (22, 23), sup-
pression of IL-12R up-regulation (24), and inhibition of CD28
signaling (25, 26). For TGF-, similar direct inhibitory effects on T
cells have been described (27–29). Contrasting reports have been pub-
lished on the interference of TGF- with IL-12 signaling (30–33).
TGF- can inhibit T cell function also indirectly via inhibitory effects
on APCs, but it seems to have paradoxical effects on proinflammatory
cytokine production depending on the cellular context (34).
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By dissecting the mechanisms of IL-10 and TGF- in the gen-
eration of LPS hyporesponsiveness and the role of IFN--produc-
ing cells in the desensitization process, we were able to demon-
strate that IL-10 and TGF- use different ways of suppressing
IFN- production, which leads to the observed differences in re-
versibility of the respective LPS-hyporesponsive states.
Materials and Methods
Cell culture
Human PBMCs were isolated from blood of healthy volunteers by Ficoll-
Paque (Amersham Biosciences, Freiburg, Germany) density gradient cen-
trifugation and cultured at 1  106 cells/ml in RPMI 1640 supplemented
with 10% FCS, 2 mM glutamine, and penicillin/streptomycin (Biochrom,
Berlin, Germany). Recombinant human IL-2, IL-10, IL-12, IL-18, and
TGF- were purchased from R&D Biosystems (Heidelberg, Germany). All
solutions were tested regularly for endotoxin contamination by TNF- re-
lease from human PBMCs. Only endotoxin-free solutions were used for
cellular experiments. Monocytes were depleted by using CD14-coated
MACS beads (Miltenyi Biotec, Bergisch Gladbach, Germany) following
the manufacturer’s protocol. Cell purity was controlled using FACS stain-
ing (CD14 cells 0.5% after depletion).
LPS desensitization and reversal
Freshly isolated PBMCs were cultured in 48-well plates and incubated for
24 h with 500 pg/ml LPS (Escherichia coli 0127:B8, Sigma-Aldrich, Hei-
delberg, Germany) or 10 ng/ml IL-10 and/or TGF- each. After this pri-
mary culture, cells were washed three times before IL-12 (10 ng/ml) and/or
IL-18 (20 ng/ml) was added. Twenty-four hours later, cells were restimu-
lated with 100 ng/ml LPS and supernatants were collected after 4 or 24 h
to measure TNF- and IFN-, respectively. For comparison of data, the
response of nondesensitized cells treated with IL-12/IL-18 was set to 100%
in each individual experiment because of donor-dependent differences.
IL-12/IL-18 response assay
Freshly isolated PBMCs were cultured at a concentration of 1  106
cells/ml in 96-well plates and stimulated simultaneously with plate-bound
anti-CD3/anti-CD28 Abs (OKT3; Janssen-Cilag, Neuss, Germany/ L293,
BD Biosciences, Heidelberg, Germany) at a concentration of 0.01 and 2
g/ml, respectively, 100 U/ml IL-2, 10 ng/ml IL-12, 10 ng/ml IL-18 and
IL-10, or 10 ng/ml TGF-. Supernatants were collected after 48 h and
IFN- concentration was measured by ELISA. For comparison of data, the
IFN- production of IL-12/IL-18-stimulated cells was set to 100% in each
individual experiment because of donor-dependent differences.
Blocking Abs against CD80/CD86 (L307.4/IT2.2; BD PharMingen,
Heidelberg, Germany) were added at a concentration of 15 g/ml simul-
taneously with the other reagents.
Analysis of cytokine production by flow cytometry and ELISA
PBMCs were stimulated with immobilized anti-CD3 mAb (0.01 g/ml)
and anti-CD28 mAb (2 g/ml), IL-2 (100 U), and IL-12/IL-18 (10 ng/ml
each) in the presence or absence of IL-10 (10 ng/ml) or TGF- (10 ng/ml)
for 30 h. After 24 h, brefeldin A (Sigma-Aldrich) was added at 5 g/ml.
Before fixation, cells were stained with the following mAbs: anti-CD16-PE
(3G8), anti-CD8-PerCP (SK1), and anti-CD3-APC (UCHTC1; all from BD
Biosciences). Cells were permeabilized and incubated with anti-IFN--
FITC mAb (25723.11; BD Biosciences) or a FITC-conjugated isotypic
control mAb (BD Biosciences) both used at 3 g/ml each. Samples were
analyzed by four-color flow cytometry on a FACSCalibur using CellQuest
software (BD Biosciences).
Concentrations of TNF- and IFN- in the culture supernatants were
determined using commercially available ELISA kits (R&D Biosystems).
The detection limit for IFN- and TNF- was 15 pg/ml.
Statistical analysis
Statistical analysis was done using the Friedman test followed by the Wil-
coxon matched pairs signed-ranked test and SPSS software (Cary, NC).
Results
Failure of IL-12 to revert IL-10/TGF--induced LPS
hyporesponsiveness is not corrected by IL-18
We have previously shown that the reduced TNF- production in
LPS-hyporesponsive monocytes could be restored to normal levels
by the addition of IFN- regardless of the desensitizing stimulus
FIGURE 1. IL-18 does not overcome the desensitizing effect of IL-10/TGF- on TNF- and IFN- production. PBMCs were incubated with the
desensitizing stimulus (LPS or IL-10/TGF-) for 24 h, washed extensively, and then either left untreated or stimulated with IL-12 and/or IL-18 as indicated.
After another 24 h, cells were restimulated with LPS and supernatants were collected after 4 or 24 h to measure TNF- (A) and IFN- (B), respectively.
The response of nondesensitized cells treated with IL-12/IL-18 was set to 100% in each individual experiment because of donor-dependent differences in
TNF- and IFN- levels. The absolute cytokine concentrations of IL-2/IL-18-treated cells (set to 100%) range from 1.4 to 15.9 ng/ml TNF- and 0.25 to
14.9 ng/ml IFN-, respectively. Data of 11 independent experiments representing 8 individual blood donors (TNF-) or 7 independent experiments
representing 6 individual blood donors (IFN-) are shown as box plots with bars representing the medians. Boxes comprise the range between the 25th and
the 75th percentile (interquartile range). The lines extending from the interquartile range include values within 1.5 times the interquartile range from the
upper or lower quartile. Points at a greater distance from the median are omitted from the graphic (outliers). The broken line indicates cytokine production
of untreated/unstimulated control cells to point out the desensitization effect. Significant differences are indicated by asterisks (, p  0.05; , p  0.01).
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(LPS vs IL-10/TGF-). The question remained why the IFN--
inducing cytokine IL-12 was able to restore LPS responsiveness
only in LPS-desensitized PBMCs but not in cells pretreated with
IL-10/TGF- or cells from immunoparalytic patients (7, 15). IL-18
has been described as another important IFN--inducing factor
that acts synergistically with IL-12 (35, 36). Therefore, we asked
whether IL-18 would be the missing factor for reversal of IL-10/
TGF--induced LPS hyporesponsiveness.
As expected, the addition of IL-18 strongly enhanced LPS-in-
duced TNF- and IFN- production in untreated control cells
compared with IL-12 alone (Fig. 1). LPS-pretreated cells produced
even higher levels of IFN- than nondesensitized cells upon ad-
dition of either IL-12 or IL-12/IL-18, while their TNF- produc-
tion was only partially restored. IL-12/IL-18 in combination en-
hanced IFN- and TNF- production also in IL-10/TGF--
pretreated cells, whereas IL-12 alone did not have any significant
effect. Nevertheless, this reversal is only partial and the production
of TNF- remains significantly diminished compared with un-
treated control cells (Fig. 1, dotted line, p  0.05). This becomes
even more obvious in comparison to control cells stimulated under
the same conditions (with IL-12/IL-18 treatment, 100% line, p 
0.01). The differences in reversibility of TNF- and IFN- pro-
duction between LPS-desensitized and IL-10/TGF--pretreated
cells remained significant (Fig. 1, p  0.05) even in the presence
of both IL-12 and IL-18. Therefore, the effect of IL-10 and TGF-
cannot entirely be explained by the inhibition of the IFN--induc-
ing cytokines IL-12 and IL-18 in LPS-hyporesponsive monocytes.
Hence, we sought other explanations for the observed differences
in reversibility.
Pretreatment with IL-12/IL-18 does not prevent IL-10/TGF--
induced LPS hyporesponsiveness
One major difference between LPS-pretreated and IL-10/TGF--
pretreated cells is the time point of exposure to IL-12/IL-18. Dur-
ing the normal course of LPS stimulation, monocytes first produce
proinflammatory cytokines including IL-12 and IL-18 followed by
the anti-inflammatory cytokines IL-10 and TGF-. Therefore, T
and NK cells first encounter IL-12, IL-18, and other proinflamma-
tory cytokines before IL-10 and TGF- are produced. This initial
contact could prevent the inhibition of IFN- production by IL-10
and TGF- and therefore enable IL-12 and IL-18 to revert LPS
hyporesponsiveness.
To test this hypothesis, we preincubated PBMCs with IL-12 and
IL-18 for 4 h before addition of IL-10 and TGF- (Fig. 2). Pre-
stimulation with IL-12/IL-18 did not prevent the establishment of
IL-10/TGF--induced LPS hyporesponsiveness nor enabled its re-
versal by IL-12/IL-18 (Fig. 2). Therefore, initial contact with IL-
12/IL-18 during the course of LPS desensitization does not provide
an explanation for the observed difference in reversibility between
the two models of LPS hyporesponsiveness.
IL-10-induced LPS hyporesponsiveness can be reverted by IL-
12/IL-18, whereas TGF--treated cells remain unresponsive
It is likely that the concentrations of endogenous IL-10 and TGF-
produced during LPS desensitization differ from the amounts of
recombinant cytokines we used to induce LPS hyporesponsive-
ness. Therefore, we investigated the individual influence of each
cytokine on the induction and reversibility of LPS hyporespon-
siveness separately.
Exogenous IL-12 only slightly increased IFN- production in
IL-10- or TGF--pretreated PBMCs (Fig. 3B) but strongly en-
hanced IFN- production in LPS-pretreated cells. This lack of re-
versibility was comparable to cells pretreated with IL-10 and
TGF- in combination (Fig. 1B). However, the addition of IL-12/
IL-18 in combination fully restored TNF- and IFN- production
in IL-10-pretreated PBMCs but not TGF--pretreated PBMCs
(Fig. 3A, p  0.01 IL-10 vs TGF-, and Fig. 3B, p  0.05 IL-10
vs TGF-). Therefore, IL-18 seems to be the missing factor to
overcome IL-10 but not TGF--induced LPS hyporesponsiveness.
IL-10 and TGF- have similar inhibitory effects on IL-12/IL-18-
induced IFN- production if permanently present
These results suggested differences in the mechanisms of IL-10
and TGF- for inhibiting IFN- production. T cells and NK cells
are the main producers of IFN- upon stimulation with LPS. This
pathway of IFN- induction is mainly mediated by IL-12 and
IL-18 but can be enhanced by other cytokines and costimulatory
molecules (11). To further investigate possible effects of IL-10 and
TGF- on IL-12/IL-18 responsiveness, we tried to simplify the
experimental setup and focused on IFN--producing cells as tar-
gets in the process of LPS desensitization.
Freshly isolated PBMCs were stimulated simultaneously with
anti-CD3/anti-CD28, IL-2, IL-12, and IL-18 in the absence or
presence of IL-10 or TGF-. In this experimental setup, which
includes T cell activation, IFN- should be induced by memory T
cells as well as NK cells. By providing rIL-12 and rIL-18, we
focused on the effects of IL-10 and TGF- on the responsiveness
of IFN--producing cells toward IL-12/IL-18.
In this experimental setup, IL-10 as well as TGF- was able to
inhibit IL-12/IL-18-induced IFN- production to a similar degree
(Fig. 4). We confirmed these results at the single-cell level by flow
cytometric analysis of intracellular IFN- expression. In contrast
to a previous report (37), our results demonstrated that IL-10 and
TGF- do not only inhibit IFN- production in CD3 T cells but
also in NK cells to a similar extent (data not shown).
At first sight, these results seem to be contradictory to the data
obtained in the LPS hyporesponsiveness model, in which IL-10-
mediated IFN- inhibition was reversible by IL-12/IL-18. How-
ever, one difference between the two models is the duration of
IL-10 presence in the culture. In the LPS hyporesponsiveness
model, inhibitory cytokines are removed before addition of IL-12/
IL-18, whereas they remain constantly present in the direct IL-12/
IL-18 response model. Therefore, we removed IL-10 and TGF-
in the direct IL-12/IL-18 response model after preincubation to
FIGURE 2. The different reversibility of LPS and IL-10/TGF--pretreated
cells is not due to different kinetics of exposure to IL-12/IL-18. PBMCs were
incubated with IL-12/IL-18 for 4 h, before the desensitizing stimulus (LPS or
IL-10/TGF-) was added. After 24 h, cells were washed extensively and then
either left untreated or stimulated with IL-12 and/or IL-18 as indicated. At
48 h, cells were restimulated with LPS and supernatants were collected after 4
or 24 h to measure TNF- ( ) and IFN- (■ ), respectively. The response of
nondesensitized cells treated with IL-12/IL-18 was set to 100%. TNF- pro-
duction is depicted as gray bars and IFN- production as black bars. One
representative experiment of two is shown.
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have comparable conditions in both models. Indeed, IL-10 lost its
inhibitory effect on IL-12/IL-18 responsiveness after removal,
whereas the inhibitory effect of TGF- was long-lasting even in its
absence (data not shown).
We conclude from these data that IFN--producing cells remain
unresponsive to IL-12/IL-18 as long as IL-10 is present. However,
these cells do not demonstrate an impaired IL-12/18-responsive-
ness after removal of IL-10 and therefore produce IFN- upon
exogenous addition of IL-12/IL-18.
The inhibitory effect of IL-10 on IL-12/IL-18-induced IFN-
production depends on the presence of monocytes
IL-10 is known to inhibit T cell function indirectly by impairing
APC function. Additionally, it has recently been shown that mac-
rophages from LPS-desensitized mice can transfer LPS hypore-
sponsiveness to nondesensitized NK/T cells, suppressing their
IFN- production (11). We therefore aimed at investigating the
role of monocytes for the inhibitory function of IL-10 and TGF-.
To this end, we depleted CD14 monocytic cells from PBMCs
using magnetic cell separation before setting up the IL-12/IL-18
response model. As shown in Fig. 5A, the inhibitory effect of IL-10
on IL-12/18-induced IFN- production was lost in the absence of
CD14 monocytes. Reconstitution of CD14-depleted PBMCs with
purified CD14 cells re-established the inhibition of IFN- pro-
duction by IL-10, which demonstrates that the inhibitory effect of
IL-10 depends on the presence of monocytes (Fig. 5B). In contrast,
the inhibitory action of TGF- was not affected by the depletion of
CD14 cells and is therefore independent of monocytes.
In our model, we tried to rule out all known effects of APCs on
IFN- production by providing these stimuli exogenously (anti-
CD3/anti-CD28, IL-2 and IL-12, and IL-18). Nevertheless, we no-
ticed a requirement for monocytes for the inhibitory action of
IL-10 and observed a decreased IFN- production in CD14-
depleted cells compared with PBMCs. Therefore, we sought for
additional monocyte-derived IFN--inducing factors that could
constitute a target of IL-10 action.
Inhibition of IL-1 and TNF- expression, but not modulation of
costimulatory molecules contributes to the inhibitory effect of IL-10
First, we investigated the role of costimulatory molecules. We de-
termined the levels of CTLA-4, inducer costimulator molecule,
and CD40 ligand in IL-12/18-stimulated T cells by FACS analysis.
Neither IL-10 nor TGF- inhibited the activation-induced up-reg-
ulation of these molecules in our system (data not shown). Fur-
thermore, the addition of blocking Abs to CD80 and CD86 neither
inhibited the production of IFN- in response to IL-12/IL-18 nor
its down-regulation by IL-10 and TGF- (Fig. 6).
Next, we looked for possible soluble mediators to enhance
IFN- production apart from IL-2, IL-12, and IL-18. We investi-
gated the involvement of IL-1 and TNF-. Both cytokines are
described as proinflammatory cytokines to be down-regulated by
FIGURE 4. IL-10 and TGF- inhibit IL-12/IL-18-induced IFN- pro-
duction in PBMCs. Freshly isolated PBMCs were stimulated with anti-
CD3/anti-CD28 Abs, IL-2, and IL-12/IL-18 as indicated. IL-10 or TGF-
was added simultaneously with the other stimuli and supernatants were
collected after 48 h to measure IFN-. Results are shown as mean values 
SD from nine independent experiments with different blood donors. IFN-
production of IL-12/IL-18-stimulated cells was set to 100% in each indi-
vidual experiment because of large interindividual variation of IFN- pro-
duction. Absolute concentrations of IFN- ranged from 13.7 to 47.3 ng/ml.
Significant differences are indicated by an asterisk (, p  0.05) and were
determined in comparison to IL-12/18-stimulated cells.
FIGURE 3. IL-12/IL-18 in combination are
able to revert IL-10- but not TGF--induced LPS
hyporesponsiveness. PBMCs were incubated with
the desensitizing stimulus (LPS or IL-10/TGF-)
for 24 h, washed extensively, and then either left
untreated or stimulated with IL-12 and/or IL-18 as
indicated. After 48 h, cells were restimulated with
LPS and supernatants were collected after 4 or
24 h to measure TNF- (A) and IFN- (B), re-
spectively. The response of nondesensitized cells
treated with IL-12/IL-18 was set to 100% as de-
scribed in Fig. 1 (indicated by the black line). Data
of 10 independent experiments representing 7 in-
dividual blood donors (TNF-) or 6 independent
experiments representing 5 individual blood do-
nors (IFN-) are shown as box plots with bars rep-
resenting the medians. Boxes comprise the range
between the 25th and the 75th percentile (inter-
quartile range). The lines extending from the in-
terquartile range include values within 1.5 times
the interquartile range from the upper or lower
quartile. Points at a greater distance from the me-
dian are omitted from the graphic (outliers).
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IL-10 in monocytes and were shown to synergize with IL-12 for
IFN- production in T cells, similar to IL-18 (38, 39). We noticed
that TNF- and IL-1 are produced at significant levels in our
IL-12/IL-18 stimulation model, which could be caused by cell-cell
contact between activated T cells and monocytes (40, 41). The
production of both cytokines was inhibited by IL-10 but not by
TGF- (data not shown). The addition of IL-1 and TNF- to
CD14-depleted cells resulted in a strong increase in IFN- pro-
duction, so that these cells reached cytokine levels of nondepleted
cells (Fig. 7).
Therefore, we asked whether the inhibition of IL-1 and TNF-
by IL-10 contributes to its inhibitory effect on cytokine-dependent
IFN- production and added rIL-1 and TNF- exogenously to
compensate for their inhibition by IL-10. Fig. 8 shows that the
inhibitory effect of IL-10 was decreased from 70% suppression in
IL-12/IL-18-stimulated cells to 30% in cells stimulated addition-
ally with exogenous IL-1 and TNF-. Nevertheless, the residual
inhibitory effect of IL-10 remained significant ( p  0.05) even
when all IFN--inducing factors (IL-12, IL-18, TNF-, IL-1)
were added in combination. This suggested that an additional IFN-
-inducing factor is produced in our system which is a target for
the inhibitory action of IL-10.
IL-15 was recently described to enhance IFN- production (42,
43). However, in our experimental setup, exogenous IL-15 did not
enhance IFN- production in the presence of IL-12/IL-18 nor re-
duce the inhibitory effect of IL-10 (data not shown). This might be
due to the presence of high amounts of IL-2 in our model, which
can be redundant to IL-15.
Exogenous addition of TGF- during LPS desensitization
prevents reversibility of LPS hyporesponsiveness by IL-12/IL-18
Our data show that only TGF- but not IL-10 can directly interfere
with IL-12/IL-18 responsiveness in IFN--producing cells. In con-
clusion, a sufficient presence of active TGF- should inhibit IFN-
production in response to IL-12/IL-18 and therefore abolish re-
versibility by IL-12/IL-18 also in the LPS desensitization model.
Nevertheless, the fact that LPS desensitization can be reverted by
IL-12/IL-18 demonstrates that IFN--producing cells remain re-
sponsive to IL-12/18 in this case. Therefore, we wondered whether
FIGURE 6. CD80/CD86 are not involved in IFN- induction or the
inhibitory effect of IL-10 or TGF-. PBMCs were simultaneously incu-
bated with anti-CD3/anti-CD28, IL-2, and IL-12/IL-18 in the presence or
absence of IL-10 or TGF- as indicated. Blocking Abs against CD80 and
CD86 or an isotypic control Ab (15 g/ml each) were added at the begin-
ning of the assay. IFN- levels were measured after 48 h by ELISA and are
shown as percentage of the IFN- response induced by IL-12/IL-18, which
was set to 100%. One representative experiment of two is shown.
FIGURE 7. IL-1 and TNF- enhance IFN- production in PBMCs
and CD14-depleted cells. PBMCs were simultaneously incubated with anti-
CD3/anti-CD28, IL-2, IL-12/IL-18, and IL-10 or TGF- as indicated. In
addition, IL-1 and/or TNF- were added at a concentration of 10 ng/ml
each. The IFN- response induced by IL-12/IL-18 in PBMCs is set at
100% in each individual experiment and all other results are shown in
relation to this. Absolute values range from 0.25 to 14.9 ng/ml IFN-.
IFN- production of CD14-depleted cells (f) is depicted compared with
PBMCs (u). Results are shown as mean values  SD from five indepen-
dent experiments with different blood donors. For statistical analysis, val-
ues of PBMCs or CD14-depleted cells were compared with the respective
cell type treated with IL-12/18 alone. Significant differences are indicated
by an asterisk (, p  0.05).
FIGURE 5. The inhibitory effect of IL-10 on cytokine-induced IFN- production depends on the presence of monocytes, whereas TGF- exerts its effect
directly on T cells. CD14 cells were depleted from freshly isolated PBMCs by using anti-CD14 MACS beads before setting up the simultaneous
stimulation assay (A). As control, we re-added CD14 cells to the depleted cells (B). In both setups, cells were stimulated with anti-CD3/anti-CD28 Abs
and IL-12/IL-18, and IL-10 or TGF- was added simultaneously. Results are shown as mean values from six independent experiments with different blood
donors. IFN- production of IL-12/IL-18-stimulated cells was set at 100% in each individual experiment and for A and B independently. Absolute IFN-
concentrations ranged from 4.1 to 29.7 ng/ml (A) and from 10.8 to 72.0 ng/ml (B). Significant differences are indicated by asterisks (, p  0.05; , p 
0.01) and were calculated in comparison to IL-12/IL-18-treated cells.
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sufficient amounts of TGF- are actually produced during LPS
pretreatment as originally suggested (6, 13).
To test this hypothesis, we added the same amount of activated
rTGF- (10 ng/ml) during LPS pretreatment as we had used for the
induction of LPS hyporesponsiveness by TGF- alone. Indeed, the
exogenous addition of TGF- during LPS desensitization rendered
these cells unresponsive to a reversal of TNF- production by
IL-12/IL-18 (Fig. 9A, p  0.05 LPS/TGF- vs LPS). Surprisingly,
we observed a significant IFN- production by these cells after
incubation with IL-12/IL-18, which was comparable to untreated
control PBMCs under the same conditions (Fig. 9B). Nevertheless,
IFN- production in LPS/TGF--pretreated cells was significantly
( p  0.05) lower compared with LPS-pretreated cells whose function
was fully restored by IL-12/IL-18. Thus, residual IFN- production
after LPS/TGF- pretreatment and IL-12/IL-18 stimulation does not
seem to be sufficient to overcome LPS hyporesponsiveness.
Therefore, we conclude that TGF- is the major factor to pre-
vent reversibility of LPS hyporesponsiveness by IL-12/IL-18 due
to its direct interference with IL-12/IL-18 responsiveness of
IFN--producing cells. The amount of TGF- produced or acti-
vated by low-dose LPS pretreatment is obviously not sufficient to
inhibit the response to exogenous IL-12/IL-18.
Discussion
The present study aimed at further investigating the role of the
anti-inflammatory cytokines IL-10 and TGF- in LPS desensiti-
zation, which is considered to be an experimental model for the
immunoparalytic state observed in late-stage septic patients. Our
results suggest that the model of LPS desensitization only partially
reflects the dysfunction of immune cells (particularly of T cells)
observed in immunoparalytic patients.
LPS desensitization was reported to be mediated by endogenous
IL-10 and TGF- and both cytokines can also directly induce a
similar state of LPS hyporesponsiveness. (6, 13). However, these
models were found to differ regarding their reversibility by IL-12
(7, 15). Remarkably, PBMCs from immunoparalytic patients
rather resembled the phenotype of IL-10/TGF--pretreated cells
than that of LPS-desensitized cells, since LPS hyporesponsiveness
of these cells was not reversible by IL-12 (15). Therefore, it
seemed important to elucidate the differences between the individ-
ual models and to investigate the mechanisms of IL-10 and TGF-
for inducing a LPS-hyporesponsive state. Our data on the different
mechanisms of IL-10 and TGF- for inhibiting IL-12/IL-18 re-
sponsiveness in T/NK cells helped to explain the observed pheno-
types of IL-12/IL-18 reversibility in the different LPS hyporespon-
siveness models (summarized in Fig. 10).
We demonstrated that the inhibitory effect of IL-10 on IFN--
producing cells is mainly due to the suppression of IFN--inducing
cytokines produced by monocytes. This explains why the substi-
tution of these factors enables the reversal of IL-10-induced LPS
hyporesponsiveness in monocytes. However, we noticed that, even
FIGURE 8. IL-1 and TNF- contribute to the inhibitory effect of
IL-10 but do not entirely account for it. PBMCs were simultaneously in-
cubated with anti-CD3/anti-CD28, IL-2, IL-12/IL-18, and IL-10 or TGF-
as described in Fig. 4. In addition, IL-1 and/or TNF- were added at a
concentration of 10 ng/ml each. IFN- levels of IL-12/IL-18 alone ( ) and
plus IL-1/TNF- (f) were set at 100% in each case to point out the
inhibitory effect of IL-10 for each stimuli. Results are shown as mean
values  SD from five independent experiments with different blood do-
nors. Significant differences are indicated by an asterisk (, p  0.05).
FIGURE 9. TGF- has an additional desensitizing effect when given simultaneously with LPS. PBMCs were incubated with the desensitizing stimulus (LPS
or LPS/TGF-) for 24 h, washed extensively, and then either left untreated or stimulated with IL-12 and/or IL-18 as indicated. Four and 24 h after restimulation
with LPS, supernatants were collected to measure TNF- and IFN- levels, respectively. Results are shown as percentage of cytokine production by IL-12/IL-
18-stimulated control cells. Data of six independent experiments from five different blood donors are depicted as box plots with bars representing the medians.
Boxes comprise the range between the 25th and the 75th percentile (interquartile range). The lines extending from the interquartile range include values within
1.5 times the interquartile range from the upper or lower quartile. Points at a greater distance from the median are omitted from the graphic (outliers). The black
line indicates cytokine production of untreated control cells stimulated with IL-12/IL-18, which was set to 100% as described in Fig. 1.
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in the presence of all IFN--inducing cytokines used in this study
(IL-12, IL-18, IL-1, IL-2, IL-15, and TNF-), IL-10 still signif-
icantly inhibited IFN- production. This suggests that either an as
yet unknown inhibitory factor is induced by IL-10 or that addi-
tional monocytic factors are involved in cytokine-dependent IFN-
production and that the production of these factors is inhibited by
IL-10. In this regard, interesting novel candidates, including the
IL-12 homologues IL-23 and IL-27, have recently been described
(44, 45), but further studies are required to determine their rele-
vance for LPS desensitization.
In contrast to IL-10, TGF- directly inhibits IFN- production
by T cells and NK cells and the LPS-hyporesponsive state induced
by TGF- is therefore not reversible by IL-12/IL-18. Because LPS
desensitization is reversible by IL-12/IL-18, a major involvement
of TGF- in its induction became rather unlikely. Indeed, addition
of recombinant TGF- during the process of LPS desensitization
rendered this model unresponsive to a reversal by IL-12/IL-18.
This suggests active TGF- as the major factor determining the
reversibility of an LPS-hyporesponsive state. Therefore, the in
vitro model of LPS desensitization is probably rather mediated by
a temporary presence of IL-10 than by TGF-. Apart from endog-
enous IL-10, other intrinsic mechanisms are likely to be involved
in LPS desensitization. Described potential mechanisms include
alteration of G protein binding (46, 47), impaired mitogen-acti-
vated protein kinase (48), or Toll-like receptor 4 signaling involv-
ing the induction of IL-1R-associated kinase M (49) and suppres-
sor of cytokine signaling 1/3 (50–52), as well as increased
expression of the p50 subunit of NF-B (53, 54). These intrinsic
mechanisms might explain why the restoration of TNF- produc-
tion did not completely correlate to the restored IFN- levels in our
experiments.
We believe that our results from this in vitro model have im-
portant implications also for the interpretation of results obtained
from in vivo LPS desensitization models as well as of clinical
observations. Recent findings in an in vivo LPS desensitization
model by Varma et al. (11) resemble several aspects of our study.
In their model, the suppression of IFN- production was also de-
pendent on the presence of macrophages, which points to an in-
volvement of IL-10 according to our results. Furthermore, T/NK
cells from LPS-tolerant mice remained fully responsive to IL-12/
IL-18 regarding IFN- production, which supports the view that at
least in this in vivo model of LPS desensitization IL-10 and not
TGF- is the dominant mediator of endotoxin tolerance.
IL-10 by itself cannot induce an immunoparalytic state in pa-
tients. We observed only a temporary immune suppression during
the treatment of psoriatic patients with IL-10 (55). These data im-
ply that, in addition to IL-10, other immunosuppressive factors
have to be involved in the pathogenesis of immunoparalysis.
TGF- is mainly regulated at the level of activation via proteo-
lytic processes rather than at the transcriptional level, and large
amounts of inactive TGF- can be found in human plasma. TGF-
can be activated by stimulated thrombocytes during inflammation
and wound healing. This process might be missing in simple mod-
els of LPS shock or desensitization. However, patients with im-
munoparalysis usually suffer from severe trauma, which can trig-
ger the activation of TGF- in vivo. Therefore, the severity of
trauma might be an additional factor contributing to the level of
immunoparalysis in patients. However, the proof for an involve-
ment of TGF- in the establishment of immunoparalysis has been
difficult to provide so far. This could be due to the fact that a local
activation of high amounts of TGF- might be sufficient to impair
T and NK cell functions. Furthermore, these investigations could
be confounded by the fact that the inhibitory effect of TGF- is
long-lasting and persists for at least 20 h.
Preliminary experiments suggest that PBMCs from septic pa-
tients with immunoparalysis show a varying responsiveness to IL-
12/IL-18 stimulation (most of them are resistant to IL-12/IL-18),
which might be due to a different level of exposure to TGF- in
vivo (our unpublished data). We are currently expanding these
investigations and their impact for prognosis in a clinical study.
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